CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies

NCT04943016 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory B-Cell Malignancies

Interventions

DRUG: CD19 Chimeric Antigen Receptor (CAR) T Cells

Sponsor

National Taiwan University Hospital